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Exploring metabolic pathway disruption in the
subchronic phencyclidine model of schizophrenia
with the Generalized Singular Value Decomposition
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Desmond J Higham1,4
Abstract
Background: The quantification of experimentally-induced alterations in biological pathways remains a major
challenge in systems biology. One example of this is the quantitative characterization of alterations in defined,
established metabolic pathways from complex metabolomic data. At present, the disruption of a given metabolic
pathway is inferred from metabolomic data by observing an alteration in the level of one or more individual
metabolites present within that pathway. Not only is this approach open to subjectivity, as metabolites participate
in multiple pathways, but it also ignores useful information available through the pairwise correlations between
metabolites. This extra information may be incorporated using a higher-level approach that looks for alterations
between a pair of correlation networks. In this way experimentally-induced alterations in metabolic pathways can
be quantitatively defined by characterizing group differences in metabolite clustering. Taking this approach
increases the objectivity of interpreting alterations in metabolic pathways from metabolomic data.
Results: We present and justify a new technique for comparing pairs of networks–in our case these networks are
based on the same set of nodes and there are two distinct types of weighted edges. The algorithm is based on
the Generalized Singular Value Decomposition (GSVD), which may be regarded as an extension of Principle
Components Analysis to the case of two data sets. We show how the GSVD can be interpreted as a technique for
reordering the two networks in order to reveal clusters that are exclusive to only one. Here we apply this
algorithm to a new set of metabolomic data from the prefrontal cortex (PFC) of a translational model relevant to
schizophrenia, rats treated subchronically with the N-methyl-D-Aspartic acid (NMDA) receptor antagonist
phencyclidine (PCP). This provides us with a means to quantify which predefined metabolic pathways (Kyoto
Encyclopedia of Genes and Genomes (KEGG) metabolite pathway database) were altered in the PFC of PCP-treated
rats. Several significant changes were discovered, notably: 1) neuroactive ligands active at glutamate and GABA
receptors are disrupted in the PFC of PCP-treated animals, 2) glutamate dysfunction in these animals was not
limited to compromised glutamatergic neurotransmission but also involves the disruption of metabolic pathways
linked to glutamate; and 3) a specific series of purine reactions Xanthine ¬ Hypoxyanthine ↔ Inosine ¬ IMP ®
adenylosuccinate is also disrupted in the PFC of PCP-treated animals.
Conclusions: Network reordering via the GSVD provides a means to discover statistically validated differences in
clustering between a pair of networks. In practice this analytical approach, when applied to metabolomic data,
allows us to quantify the alterations in metabolic pathways between two experimental groups. With this new
computational technique we identified metabolic pathway alterations that are consistent with known results.
Furthermore, we discovered disruption in a novel series of purine reactions that may contribute to the PFC
dysfunction and cognitive deficits seen in schizophrenia.
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Background
Background in neuroscience and metabolomics
Schizophrenia is characterized by deficits in cognition
known to be dependent upon the functional integrity of
the prefrontal cortex (PFC). Furthermore, compromised
PFC function in schizophrenia is supported by a multitude
of neuroimaging studies reporting hypometabolism (’hypo-
frontality’), as evidenced by decreased blood flow or glu-
cose utilization [1,2]. While the pathophysiological basis of
PFC dysfunction in schizophrenia is not completely under-
stood, a central role for NMDA receptor hypofunction is
widely supported. For example, subchronic exposure to the
NMDA receptor antagonist phencyclidine (PCP) induces
cognitive deficits and a ‘hypofrontality’ which directly par-
allels that seen in schizophrenia [3-5]. Furthermore, sub-
chronic PCP exposure induces alterations in GABAergic
cell markers and 5-HT receptor expression in the PFC
similar to those seen in this disorder [3,6,7]. While this evi-
dence places NMDA receptor hypofunction central to the
pathophysiology of PFC dysfunction in schizophrenia, the
mechanisms through which NMDA hypofunction pro-
motes PFC dysfunction are poorly understood.
Metabolomics is the comprehensive analysis of small
molecule metabolites in biological systems [8]. It involves
the study of the metabolome which is defined as all of
the small molecular weight compounds within a sample
that are required for metabolism, whose roles include
growth and functionality [9-11]. Sample sources include
bacteria, parasites, animals and humans and sample types
can include biofluids, cells or tissue extracts. Metabolo-
mics can be utilized as a tool for the characterization and
quantification of all of the metabolites in a biological sys-
tem. Its applications include profiling disease biomarkers
[12,13], monitoring disease progression [14], investigating
xenobiotic metabolism [15], investigating drug-induced
toxicity [16,17] and investigating metabolism in geneti-
cally modified animals [18]. Mass spectrometry (MS) has
been employed extensively as an analytical platform for
metabolomics studies [19-21]. The popularity of this
approach has increased over the last decade, in part due
to the advent of high resolution Fourier transform mass
spectrometers which offer improved reproducibility,
accuracy and sensitivity. This makes mass spectrometry
suitable for high throughput metabolomics studies [22].
In addition, the Orbitrap mass spectrometers that are
now available offer similar performance to FT-MS sys-
tems without the need for a high strength magnetic field
[23]. HILIC chromatography has been utilized as a
separation technique prior to MS detection of polar
metabolites in aqueous biofluids such as urine, serum
and plasma [24-30].
Additionally, it has also been used for the detection of
multiple neurotransmitters in primate cerebral cortex
[31]. HILIC chromatography has been chosen for meta-
bolomic studies as it is useful for the analysis of highly
polar metabolites which are poorly retained on reverse
phase columns [32]. Detailed reviews of the principles
and applications of HILIC have been previously outlined
[25,33]. Here, HILIC-chromatography is utilized in com-
bination with an LTQ-Orbitrap for metabolic profiling
of metabolite extracts from the PFC of control and
PCP-treated rats.
Metabolomics represents a robust approach through
which alterations in diverse metabolic pathways may be
determined at a biological systems level. In this way a
metabolomics approach may prove useful in further elu-
cidating the pathophysiological mechanisms contributing
to PFC dysfunction in schizophrenia. Furthermore, this
approach may also allow for the identification of PFC
metabolic biomarkers for the cognitive deficits in this
disorder. While the metabolomics approach can provide
a rich and comprehensive set of data, the appropriate
quantitative analysis of this data has not been adequately
developed. In particular, the identification of statistical
differences in metabolic pathways between experimental
groups rather than the identification of statistical differ-
ences in individual metabolites alone represents a major
challenge to quantitatively identifying metabolic altera-
tions at a systems level from metabolomic data. One
method through which statistical differences in meta-
bolic pathways can be identified from metabolomic data
involves the representation of this data as a large, com-
plex network of nodes (single metabolites) connected by
real-value edges (the correlation coefficient between two
metabolites). This form of representation has high face
validity as the relationship between two metabolites, in a
given pathway, is governed by a single or series of enzy-
matic reactions that can be viewed as being represented
by the correlation between the concentrations of the
two metabolites. Another advantage is that metabolomic
data consist of a range of metabolites detected in both
of the experimental groups of interest meaning that
these data can be expressed as two complex networks
based upon the same set of nodes. This data structure is
amenable to analysis through the application of the
Generalized Singular Value Decomposition (GSVD)
algorithm.
Background in network science and spectral methods
Large, complex interaction networks arise across many
applications in science and technology [34-36]. Spectral
methods, based on information computed from eigen-
vectors or singular vectors, have been used successfully
to reveal fundamental network properties. For example,
we may wish to cluster objects into groups [37], put
objects into order [38] or discover specific patterns of
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connectivity within subgroups [39-42]. In this work, we
look at the case where two interaction data sets are
available and the aim is discover differences between the
two sets in the form of mutually exclusive clusters. For
example, a given group of biologically defined entities,
such as genes, proteins, metabolites or brain regions,
may contain a subgroup that behaves in a coordinated
manner under one condition, or in one organism, but
not in another–the network with respect to one type of
interaction contains a cluster that is not present in the
other. We will show that the Generalized Singular Value
Decomposition, which is becoming more widely used in
computational biology [43,44] can be justified as the
basis of a network reordering approach. We also con-
sider how to quantify the statistical significance of net-
work patterns that are uncovered.
Overall, this work develops and applies a novel algo-
rithm in network science and shows that it reveals
meaningful insights when applied to cutting-edge meta-
bolomic data.
Results
Derivation of new algorithm
Suppose that the square, symmetric, real-valued
matrices A and B in ℝN×N represent two different types
of interaction between a set of N nodes. We have in
mind the case where the weights play the role of corre-
lation coefficients. Our aim is to discover clusters, in the
sense of subsets of nodes that are mutually, pairwise,
strongly connected through positive weights. The algo-
rithm will also discover clusters of strong negative con-
nectivity, although in practice this type of pattern is less
likely to be present. However, we note that the argu-
ments given below and the resulting algorithm remain
valid in the case where the weights are non-negative,
with zero representing the minimal level of similarity.
The novelty of our approach is that in order to reveal
interesting differences between the two types of connec-
tivity data, we look for a set of nodes that form a good
cluster with respect to A and a poor cluster with respect
to B, or vice versa. As a starting point for a computa-
tional algorithm, we consider the identity
||Ax||22 =
N∑
k=1
x2k deg
A
k +
N∑
i=1
N∑
k=1
N∑
l=1,l=k
aikailxkxl, (1)
for x Î ℝN. Here ||·||2 denotes the Euclidean norm
and degAk :=
∑N
j=1 a
2
kj is one way to generalize the con-
cept of out-degree to the case of a weighted network.
Suppose we wish to split the nodes into two groups
such that nodes within each group are well-connected
but nodes across different groups are poorly connected.
We could use an indicator vector x Î ℝN to denote
such a partition, with xs = 1 if node s is placed in group
1 and xs = -1 if node s is placed in group 2.
Fixing on two nodes, k and l, we could argue that the
existence of a third node, i, such that aik and ail are
both large and positive or both large and negative is evi-
dence in favor of placing k and l in the same group
(since they have in common a strong similarity or dis-
similarity with node i). On the other hand small or
oppositely signed values for aik and ail is evidence in
favor of placing k and l in different groups. In terms of
the indicator vector, this translates to
1. aikail large and positive ⇒ try to choose xkxl = +1,
2. aikail small or negative ⇒ try to choose xkxl = -1.
Returning to the right-hand side of (1), we see that∑N
k=1 x
2
k deg
A
k is independent of the choice of indicator
vector, and
∑N
i=1
∑N
k=1
∑N
l=1,l=k aikailxkxl gives a measure
of how successfully we have incorporated the (possibly
conflicting) desiderata in points 1 and 2 over all pairs k,
l and third parties i. So we could judge the quality of an
indicator vector by its ability to produce a large value of
||Ax||22, provided other constraints, such as balanced
group sizes, were satisfied.
Analogously, we can argue that making∑N
i=1
∑N
k=1
∑N
l=1,l=k
aikailxkxl as negative as possible is a
good way to avoid forming well-connected subgroups,
and so the problem
max
xs∈±1, 1≤s≤N
||Ax||22
||Bx||22
(2)
is a good basis for picking out strong clusters in A
that are not present in B.
In general, optimizing over a large, discrete set of pos-
sibilities is computationally intractable, and hence we
will follow the widely used practice of relaxing to an
optimization over ℝN[37,45]. This approach goes back
as far as the pioneering work of Fiedler [46] and has
some theoretical underpinning in the case where a sin-
gle network is analyzed [47,48]. So, instead of (2) we
have
max
x∈RN , x =0
||Ax||22
||Bx||22
. (3)
At this stage we recall that a general pair of matrices
A Î ℝm×n and B Î ℝp×n can be simultaneously factor-
ized using the Generalized Singular Value Decomposi-
tion (GSVD) into
A = UCX−1 and B = VSX−1, (4)
where U Î ℝm×m and V Î ℝp×p are both orthogonal,
X Î ℝn×n is invertible, C Î ℝm×n and S Î ℝp×n are diag-
onal with nonnegative entries such that C = diag(c1, c2,..,
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cn) and S = diag(s1, s2,..., sq) with q = min(p, n), and 0 ≤
c1 ≤ c2 ≤ ··· ≤ cn and s1 ≥ s2 ≥ ··· ≥ sq ≥ 0 [49]. The ratios
li = ci/si are the generalized singular values of A and B.
A key property of the GSVD is that the columns of X
are stationary points of the function f :ℝn ↦ ℝ given by f
(x) = || Ax ||2 /||Bx ||2, with the generalized singular
values li giving the corresponding stationary values.
Hence, we may tackle the problem (3) through the
GSVD. Columns 1, 2, 3,... of X are candidates for finding
good clusters in B that are poor clusters in A and,
analogously, columns N, N - 1, N - 2,... of X are
candidates for finding good clusters in A that are poor
clusters in B.
To transform back from real to discrete domains, we
may use the ordering of the elements in x to define a
new ordering for the two networks. More precisely, we
relabel row and column i of A and B as row and column
pi, where
pi ≤ pj ⇔ xi ≤ xj.
In this way, the existence or lack of clusters in each
network becomes apparent from inspection of the heat
map of the reordered matrix. This is the approach that
we use. We will also show that p-values can be com-
puted to quantify the statistical significance of the
results. The issue of fully automating the choice of clus-
ter size is left as future work.
A variant of the algorithm
In our context, the matrices A and B are square, with m
= n = p = N. In this case, if we make the additional
assumption that A and B are invertible it is known that
the GSVD is closely related to the standard Singular
Value Decompositions (SVD) of AB-1 and BA-1. To see
this, we could rearrange (4) into
AB−1 = UCS−1VT and BA−1 = VSC−1UT . (5)
Alternatively, we may let z = Ax or y = Bx in (3), to
obtain the quadratic problems
max
z∈ RN , z =0
||z||22
||BA−1z||22
or max
y∈ RN , y =0
||AB−1x||22
||y||22
,
which can be solved through the standard SVD.
It is known from spectral graph theory that the domi-
nant singular vectors give good directions in which to
look for clusters [37,50]. Inverting the weight matrix
reverses their importance (the singular values becomes
s
-1) and hence a spectral clustering approach applied
to A-1 will typically find the opposite of good clusters–
poorly connected nodes will be grouped together [51].
So, intuitively, forming AB-1 in (5) should produce a
data matrix for which the SVD approach finds good
clusters for A and poor clusters for B. Analogously, the
opposite holds for BA-1.
Having interpreted the algorithm this way, it is then
natural to consider the reverse products, A-1B and B-1A,
or, equivalently, to form the optimization problem
max
x∈ RN , x =0
||B−1x||22
||A−1x||22
. (6)
We may interpret (6) from the point of view that
making B-1x large encourages poor clusters for B, while
making A-1x small encourages good clusters for A. In
this case, we would base our algorithm on the GSVD of
A-1 and B-1.
In the situation where A and B are both symmetric,
corresponding to undirected networks, we have, from
(4),
A−1 = (AT)−1 = (X−TCUT)−1 = UC−1XT
and
B−1 = (BT)−1 = (X−TSVT)−1 = VS−1XT .
Then we may appeal to the arguments given pre-
viously and use columns from the inverse of the third
factor in the GSVD as the basis for reordering. With
this approach we use columns of X -T rather than col-
umns of X. We emphasize that although this heuristic
derivation used an assumption that A and B are inverti-
ble, the GSVD, and hence the final algorithm, applies in
the non-invertible case. Also, the algorithms that we use
do not require the computation of matrix inverses.
In tests on both synthetic and real network pairs, we
found that this version of the algorithm was more effec-
tive, [52]. Hence, in this work we focus on the approach
of reordering networks pairs via columns of X -T. In
summary, the first few columns of X -T should give
orderings that favor clusters in B rather than A and vice
versa for the final few columns. In our computational
examples, we used the gsvd routine built in to MATLAB
http://www.mathworks.com/.
Synthetic test on binary networks
In this section we illustrate the algorithm in a simple,
controlled case where we know the “correct” answer.
We begin by considering binary networks, where results
can be clearly visualized. We generated binary adjacency
matrices A and B as shown in Figure 1. Here we have
20 nodes. In both networks, nodes 1-5 are well con-
nected. In A there is a well connected cluster consisting
of nodes 6-15, whereas in B there is a well connected
cluster consisting of nodes 15-20. To make the test
more realistic, the clusters are not perfect; there are
both missing edges (false negatives) within the clusters
Xiao et al. BMC Systems Biology 2011, 5:72
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and spurious edges (false positives) outside the clusters.
Our aim is to test whether the algorithms can identify
the clusters that are particular to each data set. We then
show how statistical significance can be quantified.
We emphasize that the node labeling in Figure 1 was
chosen purely to make the inherent structure visually
apparent. Any spectral reordering algorithm should be
invariant to a relabeling of the input data. In our con-
text, this follows from the fact that for any permutation
matrix P, the factorizations A = UCX -1 and B = V SX -1
are equivalent to PAPT = (PU)C(PX) -1 and PBPT =
(PU)S(PX) -1. So, on the relabeled data matrices, (PX)
plays the role that was played by X, and our algorithm
reorders based on the appropriately permuted columns
of X -T, as required. In Figure 2 we show the same two
data sets with an arbitrary relabeling in order to illus-
trate that the inherent structure is no longer apparent.
In essence, we are hoping that the algorithm will find
the structure that has been buried in Figure 2.
In Figure 3 we display the two adjacency matrices
reordered with the algorithm; we show reordering with
eight different columns of X -T, four from each end of
the spectrum. We see that mutually exclusive structures
have been uncovered. The reordering from the first col-
umn begins with nodes 18, 20, 16, 15, 19, 17, which
form a cluster in B, but not A. The final column begins
by picking out nodes 7, 9, 10, 15, 14, 11, 6, 13, which
form the bulk of the 6-15 cluster in A. Nodes 8 and 12,
which are missing from this sequential ordering, are
placed at the head of the ordering in the penultimate
column, which begins 12, 8, 7, 10, 15, 14, 9, 11. So in
summary, the 19th and 20th columns of X -T each
reveal almost complete information about the exclusive
cluster in A, and between them they capture the full
cluster.
Cluster validation
Suppose we find τ nodes giving a good cluster s for B
but a poor cluster for A when the graphs are reordered
by column v from X -T. Is this type of substructure likely
to arise “by chance"? The following general approach
can be used in order to determine a p -value, where we
will regard a value below 0.05 as indicating statistical
significance.
Initialization: Compute a measure of cluster quality, c
(A, B), for the promising substructure consisting of
those τ nodes in networks A and B reordered by column
v.
Step 1: Randomize the networks and obtain new data
sets Aˆ and Bˆ.
Step 2: Compute the GSVD for the randomized net-
works Aˆ and Bˆ and obtain a matrix Xˆ−T.
Step 3: Compute the measure c(Aˆ, Bˆ) for the τ node
‘cluster’ in Aˆ and Bˆ reordered by column v from Xˆ−T.
p -value After performing M loops over Steps 1 to 3,
compute a p -value as the proportion of c(Aˆ, Bˆ) samples
that exceed c(A, B).
For our cluster quality measure c(A, B) we used
(density of edges within the cluster inB)/(density of edges outside the cluster inB)
(density of edges within the cluster inA)/(density of edges outside the cluster inA)
.
For these binary graphs, the density f (s) of cluster s
was defined as
f (s) =
|E(s)|
|s|
. (7)
Here, |E(s)| represents the actual number of edges in
the object block s, and |s| is the maximum possible
number of edges.
For weighted graphs, in the case where the cluster is
dominated by positive weights, we will generalize this to
f (s) =
w(s)
|s|
. (8)
Here, w(s) denotes the average weight in block s. We
note the denominator |s| cancels when ratios are com-
puted in the p-value algorithm.
In Figure 3, we see that eight nodes
7,9,10,15,14,11,6,13 form a cluster in A, but not in B,
Figure 1 Adjacency matrices for the two synthetic networks.
Figure 2 Relabeled versions of the synthetic networks in
Figure 1.
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when the synthetic data is reordered with the final col-
umn of X -T. Applying the procedure above, using per-
mutation to randomize the networks M = 1000 times as
described below, we obtained a p-value of 0.007. Apply-
ing the same procedure, we also obtained a p-value of
0.029 for the first 6 nodes 18, 20, 16, 15, 19, 17 when
the synthetic data is reordered with the first column of
X -T, which visually form a cluster in B, but not in A.
These p-values (< 0.05) both indicate that the results are
statistically significant. As a further test, we arbitrarily
Figure 3 Networks reordered using columns of X -T.
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selected the subnetworks of A and B composed of nodes
2,4,12,16,1,3,18, which correspond to the 12th to 18th
components of the sorted final column from X -T. In
this case, we would not expect to find a significant
result. This is reflected in the large p-value of 0.844. In
more exhaustive experiments, three randomization
methods were tested [52]:
• Erdös-Rényi: generate a classical random graph with
the appropriate number of edges.
• Redistribution: redistribute the entries in each row
and each column of A, and perform the same operations
on B.
• Permutation: reorder the nodes in A and B and
choose the first τ nodes in this new ordering. In this
case, recomputation of the GSVD in Step 2 is not neces-
sary, due to the permutation invariance of the
factorization.
Of those three approaches, Erdös-Rényi may be the
most commonly used method to randomize a binary
network, whereas permutation extends most naturally to
the case of weighted edges, so we used permutation in
the test shown here. We also tested another simple clus-
ter quality measure which is the ratio of density of edges
within the cluster in one graph and that in the other
graph.
These variations were studied within this general
methodology on both real and synthetic data sets [52].
In all cases, comparable p -values were produced.
Synthetic test on correlation networks
Having tested the algorithm on binary networks, we
now consider the case where weighted edges arise as
correlation coefficients.
First, we generate two correlation matrices A and B as
shown in Figure 4. Here, each graph has 20 nodes, and
each entry is real valued, representing the correlation
coefficient between the corresponding nodes. The same
cluster patterns given for the synthetic binary matrices
in Figure 1 were built in to the synthetic correlation
data: nodes 1-5 are well connected in both networks; in
A there is a well connected cluster consisting of nodes
6-15, whereas in B there is a well connected cluster con-
sisting of nodes 15-20. Some noise was added to the
clusters to make this test more realistic.
More precisely, in our computation, the value of
each entry (the correlation coefficient) in A and B as
shown in Figure 4 is generated from a pair of 20 × 50
rectangular matrices Da and Db. The corresponding
cluster patterns are built from signals. Figure 5 shows
the nine signals that take part in the data. These are
row vectors with 50 elements. We use v[1], v[2], v[3],...,
v[9] to denote them. From these signals, we set up two
matrices
• Da Î ℝ
20×50: the first 5 rows are linear combina-
tions of v[1], v[2], v[3], v[4], v[5], v[6] and v[7]. Rows 6
to 15 are combinations of v[7] and v[8]. The remain-
ing rows (rows 16 to 20) are Gaussian pseudoran-
dom numbers.
• Db Î ℝ
20×50: the first 5 rows are linear combina-
tions of v[1], v[2], v[3], v[4], v[5], v[6] and v[7]. Rows 6
to 14 are Gaussian pseudorandom numbers. The
remaining rows (rows 15 to 20) are combinations of
v[4] and v[9].
Building up the rows from the underlying signals in
this manner allowed us to construct the correlation pat-
terns seen in Figure 4.
Although the algorithm is invariant to permutation,
for visual clarity, we also shuffled the synthetic correla-
tion data sets A and B before applying our algorithm to
them. Figure 6 shows the same synthetic correlation
data sets with an arbitrary relabeling.
We present the results from our algorithm in Figures
7 and 8. We show the relabeled A and B reordered with
two extreme columns of X -T, one from each of the two
ends of the spectrum. The reorderings reveal the
mutually exclusive cluster structures of A and B. We
also applied the cluster validation method to the struc-
tures uncovered by the reorderings using random
Figure 4 The original synthetic correlation data.
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permutation. In Figure 7 we see that the first column of
X -T picks out the continuous nodes 17, 15, 20, 18, 16,
19, which form a good cluster in B but not in A (p <
0.001). The reordering from the final column of X -T
shown in Figure 8 reveals that the 6-15 cluster in A but
not in B was completely uncovered by the nodes 10, 14,
12, 9, 8, 7, 6, 13, 15, 11 (at the top left hand side of the
heatmaps, p < 0.001).
In summary, this additional synthetic test illustrates
that our GSVD based algorithm can be extended to
Figure 5 The nine signals.
Figure 6 Relabeled versions of the synthetic networks in Figure 4.
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reveal the pattern difference between two relative corre-
lation matrices in terms of clustering.
Quantitative determination of metabolic pathways
disrupted in the prefrontal cortex of PCP-treated animals
SIEVE analysis (Thermo-Fisher Scientific) revealed sig-
nificant PCP-induced alterations in the level of specific
metabolites in the PFC of PCP-treated rats (Table 1
Additional File 1). These changes were evident in multi-
ple metabolic pathways as defined by the Kyoto Ency-
clopedia of Genes and Genomes (KEGG) metabolite
pathways database. Significant changes were evident in
(i) glutamate metabolism (3 metabolites [m, n]), (ii) the
alanine, aspartate and glutamate pathway (2 metabolites
[n]), (iii) phenylalanine, tyrosine and tryptophan meta-
bolism (3 metabolites [a]), (iv) purine metabolism (2
metabolites [o]) and (v) butanoate metabolism (2 meta-
bolites [k]). This suggested that these metabolic path-
ways are disrupted in the PFC of PCP-treated animals.
However, this simple level of analysis prevents any
quantitative and statistically rigorous determination of
the predefined (KEGG) metabolic pathways disrupted in
the PFC of PCP-treated animals.
In the context of this study the aim of applying the
GSVD algorithm to metabolomic data from control and
PCP-treated animals was to quantitatively determine
which predefined metabolic pathways were altered in
PCP-treated animals. The inter-metabolite Pearson’s
correlation coefficient (partial correlation) was used as
the metric of the functional association between each
pair of metabolites and was generated from the metabo-
lite peak intensities, as determined by Liquid Chromato-
graphy Mass Spectrometry (LC-MS), across all animals
within the same experimental group (i.e. either control
or PCP-treated). These correlations were Fisher trans-
formed to give the correlation data a normal distribu-
tion. This resulted in a pair of symmetric, square, real-
valued {98 × 98} partial correlation matrices (Control
Figure 7 The synthetic correlation data reordered with the first column from X -T.
Figure 8 The synthetic correlation data reordered with the final column from X -T.
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animals: Additional File 2 PCP-treated animals: Addi-
tional File 3). Each within-group matrix represents the
specific association strength between each of the 9506
possible pairs of metabolites in that experimental group.
In the simplest biological case the correlation coefficient
between two metabolites (nodes) in the matrix repre-
sents the series of enzymatic reactions responsible for
converting one metabolite into another. However, it
should be noted that this simple interpretation does not
account for the complex relationships that may influ-
ence the correlation between two metabolites, such as
the involvement of metabolites in alternative, often par-
allel, metabolic pathways. There are important limita-
tions that must be recognized when modeling
metabolomic data as a complex network of interactions
between metabolites (as defined by the correlation that
exists between them) such as the potential for correla-
tions to exist between metabolites that are not biologi-
cally relevant. The impact of such erroneous
associations on the interpretation of the data as outlined
in this paper will be limited by the approach of charac-
terizing alterations at the level of metabolic pathways,
involving multiple metabolites (the approach taken in
this study), rather than considering the disruption of
single correlation coefficient between two metabolites.
Our network treats interactions between molecules as
bidirectional, and so the set of interactions between
molecules forms an undirected weighted network. In
essence the GSVD algorithm allows the reordering of
the two experimental matrices A (control animals) and
B (PCP-treated animals) with the aim of discovering a
new node (metabolite) ordering that reveals clusters of
nodes that exhibit strong connectivity (mutual weights)
in one network but not the other. In the context of this
data the GSVD algorithm was used to identify clusters
of metabolites present in one experimental group that
are not present in the other with the aim of identifying
those metabolic pathways in the PFC disrupted by PCP
treatment. Once the matrices had been reordered
through the GSVD algorithm the significant presence of
a cluster in the given network was statistically tested by
comparison of the cluster quality measure in the real
networks relative to that in 1000 random permutations
of the initial matrices. The original metabolomic net-
works are shown in Figure 9, where matrix A represents
control animals and B represents PCP-treated animals.
Figures 10 and 11 show the networks reordered by the
first and the final column of X -T, respectively. The ori-
ginal position of each metabolite detected by LC-MS
(Figure 9) and its new position in each of the reordered
matrices (Figures 10 and 11) are shown in Additional
File 4. Visually, in Figure 10 there was no obvious pat-
tern of clustering that would identify significant clusters
of metabolites present in PCP-treated animals that were
Table 1 PCP-induced alterations in PFC metabolite levels as determined by SIEVE analysis
Formula Metabolite Metaboite
KEGG ID
KEGG
Pathways
P -value Ratio
C9H11NO3 L-Tyrosine c00082 ko00350, ko00360, ko00400 0.001 0.584
C10H17N3O6 gamma Glutamylglutamine NA NA 0.007 0.673
C6H13N3O3 L-Citrulline c00327 ko00330 0.007 0.709
C3H7NO2S L-Cysteine c00097 ko00260, ko00270, ko00430, ko00480, ko00730, ko00770, ko00920 0.012 0.445
C8H9NO 2-Phenylacetamide c02505 ko00360 0.015 0.561
C9H8O3 Phenylpyruvate c00166 ko00360, ko00400 0.016 0.57
C4H6O2 2,3-Butanedione c00741 map00650 0.017 0.786
C4H5N3O Cytosine c00380 ko00240 0.019 0.665
C04H9NO2 GABA c00334 ko00250, ko00330, ko00410, ap00650, ko04080 0.021 0.804
C9H17NO4 O-Acetylcarnitine c02571 ko00250 0.022 2.649
C14H18N5O11P Adenylosuccinate c03794 ko00230, ko00250 0.029 3.276
C5H5N5O Guanine c00242 ko00230 0.035 0.593
C7H16NO3 Carnitine c00487 ko00310 0.037 0.819
Table 1 shows the molecular formula, tentative metabolite identity and the KEGG pathways in which a metabolite is involved. Only metabolites found to be
significantly different between the two experimental groups by SIEVE analysis (see Methods section) are shown. Full data for all metabolites detected in the PFC
of control and PCP-treated rats are shown in Table S1 (Additional File 1). The most prominent alterations in KEGG defined metabolic pathways appeared to be in
(i) alanine, aspartate and glutamate metabolism (3 metabolites [ko00250]), (ii) phenylalanine, tyrosine and tryptophan metabolism (3 metabolites [ko00360]), (iii)
purine metabolism (2 metabolites [ko00230]) and (iv) butanoate metabolism (2 metabolites [ko00650]). KEGG defined metabolic pathways; ko00250: Alanine,
Aspartate and Glutamate metabolism; ko00330: Arginine and Proline metabolism; ko00410: beta-Alanine metabolism; map00650: Butanoate metabolism; ko00270:
Cysteine and Methionine metabolism; k00480: Glutathione metabolism; ko00260: Glycine, Serine and Threonine metabolism; ko00430: Methionine metabolism;
ko04080; Neuroactive ligand-receptor interaction; ko00770: Pantoate and CoA biosynthesis; ko00360: Phenylalanine metabolism; ko00400: Phenylalanine, Tyrosine
and Tryptophan biosynthesis; ko00230: Purine metabolism; ko00240: Pyrimidine metabolism; ko00920: Sulphur metabolism; ko00430: Taurine and Hypotaurine
metabolism; ko00730: Thiamine metabolism; ko00350: Tyrosine metabolism; ko00400: Tyrosine and Tryptophan biosynthesis. NA denotes a metabolite not
associated with a KEGG compound ID or KEGG pathway.
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not present in controls. In contrast, in Figure 11 there
appeared to be clusters of metabolites present in the
PFC of control animals that were not present in PCP-
treated animals (top left and bottom right hand side of
the heatmap). For Figure 11 the significance of the top
cluster (first 22 nodes in the reordering, p < 0.001) and
the bottom cluster (last 18 nodes in the reordering, p <
0.001) was confirmed, indicating that there were clusters
of metabolites significantly present in control (A) ani-
mals that were not present in PCP-treated (B) animals.
The identity of the metabolites, the KEGG pathways in
which each metabolite is involved, and the PCP-induced
alteration in the overt level of each metabolite (as deter-
mined by SIEVE analysis) are shown in Tables 2 and 3
for the top and bottom cluster, respectively. In contrast
to the metabolite clustering shown in Figure 11 there
was no evidence in Figure 10 for any significant cluster
of metabolites present in PCP-treated animals (B) that
was not present in control (A) animals: (i) potential top
cluster [first 10 nodes] p = 0.421; (ii) potential middle
cluster [nodes 18-25] p = 0.494.
Rigorous significance testing, involving multiple poten-
tial metabolite clusters, confirmed that there were no
significant clusters of metabolites in PCP-treated ani-
mals that were not present in controls (Figure 10). Fol-
lowing significance testing of potential metabolite
clusters in the GSVD reordered matrices, hypergeo-
metric probability (described in the Methods section)
was applied to test the significance of KEGG defined
metabolite pathway over-representation in these clusters.
The results for hypergeometric probability testing are
shown in Tables 4 and 5.
Discussion
Through its application to metabolomic data we have
clearly demonstrated the added value that can be gained
from applying the GSVD algorithm to two sets of com-
plex, network data based upon the same set of nodes. In
particular, we have demonstrated that the combined
application of the GSVD algorithm with hypergeometric
probability analysis provides an analytical framework by
which statistical alterations in predefined metabolic
Figure 9 Control and PCP: original ordering.
Figure 10 Control (A) and PCP (B): reordered with the first column from X -T.
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Figure 11 Control (A) and PCP (B): reordered with the final column of X -T.
Table 2 Metabolite identities and their relevant KEGG pathways in the top cluster of Figure 11
Formula Metabolite Metaboite
KEGG ID
KEGG
Pathways
P
-value
Ratio
C5H10N2O3 L-Glutamine c00064 Ko00230, ko00240, ko00250, ko00330 0.522 0.959
H3PO4 Phosphoric acid c00009 ko00190 0.254 0.915
C5H7NO3 1-Pyrroline-4-hydroxy-2-
carboxylate
c04282 ko00330 0.781 0.981
C4H9N3O2 Creatine c00300 ko00330, ko00260 0.551 0.953
C4H9NO2 GABA c00334 ko00250, ko00330, ko00410, ko04080, map00650 0.021 0.804
C4H7NO4 L-Aspartate c00049 ko00250, ko00260, ko00270, map00300, ko00330, ko00340, ko00410,
ko00760, ko00770, ko04080
0.319 0.916
C4H7NO2 1-Aminocyclopropane-1-
carboxylate
c01234 ko00270, ko00640 0.590 0.951
C5H5N5O Guanine c00242 ko00230 0.035 0.593
C5H9NO4 Glutamate c00025 ko00250, ko00330, ko00340, ko00471, ko04080, ko00480, map00650 0.845 0.985
C4H7NO Hydroxymethylpropanitrile NA NA 0.098 0.842
C6H6N2O Nicotinamide c00153 ko00760 0.440 0.917
C4H6O2 2,3-Butanedione c00741 map00650 0.017 0.786
C6H12O4 Pantoate c00552 ko00770 0.722 0.963
C15H23N5O14P2 ADP-ribose c00301 ko00230 0.058 677.029
C3H7NO3 L-Serine c00065 ko00260, ko00270, ko00600, ko00920, ko00680 0.316 0.856
C4H5N3O Cytosine c00380 ko00240 0.019 0.665
C2H7NO3S Taurine c00245 ko00430, ko04080 0.936 0.995
C4H5NO3 Maleamate c01596 ko00760 0.372 0.927
C2H8NO4P Ethanolamine phosphate c00346 ko00260, ko00564, ko00600 0.373 0.889
Unknown ID NA NA 0.271 1.395
C5H11NO3 Hydroxyvaline NA NA 0.585 0.946
C6H13N3O3 L-Citrulline c00327 ko00330 0.007 0.709
Table 2 shows the top cluster of metabolites identified by the GSVD algorithm that are present in the PFC of control but not PCP-treated animals (Figure 11). The
molecular formula, tentative molecular identity, its KEGG compound identity and the KEGG metabolic pathways in which a given metabolite is involved are also
shown. The key for each KEGG pathway identity is shown in Table 4. The p -values and ratio change reported for each metabolite in this table are those
calculated by SIEVE analysis. Those metabolites found to be significantly different between the two groups by analysis are highlighted in bold. While SIEVE
analysis fails to attribute significance (p < 0.05) to PCP-induced alterations in the overt concentration of many metabolites in this cluster, GSVD analysis reveals
that the relationship between these metabolites is significantly altered by PCP treatment (p < 0.001), highlighting the specific metabolic pathways that may be
disrupted in the PFC of PCP-treated animals. The most prominent alterations in KEGG defined pathways in this cluster were in (i) Arginine and Proline
metabolism (7 metabolites [ko00330]) (ii) Glycine, Serine and Threonine metabolism (3 metabolites [ko00260]) and (iii) KEGG defined neuroactive ligands (4
metabolites [ko04080]).
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pathways between experimental groups can be defined
from complex metabolomic data. There is a great unmet
need for this type of analytical approach in metabolo-
mics, as well as in the other -omics fields (e.g. transcrip-
tomics), which allows the quantification of alterations at
the biological systems (pathways) level rather than sim-
ply identifying significant alterations of discrete mea-
sures (i.e. single metabolites).
Through the application of this analytical approach we
identified statistically significant alterations in specific,
pre-defined metabolic pathways (KEGG database path-
ways) that may contribute to PFC dysfunction in PCP-
treated animals, and so in schizophrenia. This included
the disruption of the (1) Alanine, Aspartate and Gluta-
mate [ko00250], (2) Arginine and Proline [ko00330], (3)
Butanoate [ko00650], (4) Nicotinate and Nicotinamide
[ko00760], (5) Glycine, Serine and Threonine metabolic
pathways as well as an imbalance in (6) metabolites
active as neurotransmitter ligands [ko04080]. The dis-
ruption of metabolic pathways involving glutamate in
the PFC of PCP-treated rats seems particularly pertinent
given the reported alterations in extracellular glutamate
availability in the PFC following repeated PCP treatment
[53] and the central hypothesis of hypofunctional gluta-
matergic PFC neurotransmission in schizophrenia
[54,55]. In addition to altered glutamate metabolism
there was also evidence to support an imbalance in mul-
tiple metabolites known to be active at glutamate recep-
tors. This included an imbalance in the relationship
between glutamate, L-aspartate and Tauring (Table 2)
which are all known to be active at glutamate receptors.
Furthermore, evidence for the disruption of glycine, ser-
ine and threonine metabolism may suggest that glycine
and serine activity as co-agonists at the NMDA recep-
tors may be disrupted in the PFC of PCP-treated ani-
mals. However, it is important to note that we failed to
detect glycine levels in our samples and serine levels
appear to be overtly unchanged. The possibility of
altered glycine levels in the PFC of PCP-treated rats
warrants further investigation given the ability of glycine
and NMDA receptor glycine site agonists to reverse
subchronic PCP-induced alterations in PFC dopaminer-
gic neurotransmission [56,57], which may be central to
the impact of subchronic PCP treatment on cognition.
Table 3 Metabolite identities and their relevant KEGG pathways in the bottom cluster of Figure 11
Formula Metabolite Metaboite
KEGG ID
KEGG
Pathways
P -value Ratio
C5H4N4O2 Xanthine c00385 ko00230 0.339 0.508
C10H16N2O7 Gamma-
glutamylglutamic acid
NA NA 0.143 0.54
C14H26O2 Myristoleic acid c08322 NA 0.689 0.623
C5H4N4O Hypoxanthine c00262 ko00230 0.115 0.569
C17H37NO2 Heptadecasphinganine NA NA 0.733 0.769
C10H13N4O8P Inosine monophosphate c00130 ko00230 0.461 0.73
C10H17N3O6 Peptide fragment (Arg-Arg-Gln) NA NA 0.775 1.183
C6H15NO3 Triethanolamine c06771 ko00564 0.691 1.207
C9H14N4O3 Carnosine c00386 ko00340, ko00410 0.872 1.128
C10H12N4O5 Inosine c00294 ko00230 0.090 0.6
C15H12O5 Narigenin c00509 NA 0.196 0.862
C10H17N3O6 gamma Glutamylglutamine NA NA 0.007 0.673
C26H42N7O20P3S 2-Hydroxyglutaryl-CoA c03058 map00650 0.179 0.715
C31H54N7O17P3S Decanoyl-CoA c05274 ko00071 0.410 1.312
C25H44NO7P 2- Aminoethylphosphocholate c05683 ko00440 0.243 0.662
C22H26O6 Eudesmin NA NA 0.084 0.493
C3H7NO2S L-Cysteine c00097 ko00260, ko00270, ko00430, ko00480, ko00730, ko00770, map00920 0.012 0.445
C3H7O6P ) Glycerone phosphate c00111 ko00010, ko00051, ko00052, ko00561, ko00562, ko00564, ko00620 0.063 0.381
Table 3 concerns the bottom cluster of metabolites identified by the GSVD algorithm that are present in the PFC of control animals but not PCP-treated animals.
The molecular formula, tentative molecular identity, its KEGG compound identity and the KEGG metabolic pathways in which a given metabolite is involved are
shown. The identity of each KEGG pathway ID is shown in Table 5. The p -values and ratio change reported for each metabolite in this table are those calculated
by SIEVE analysis. Those metabolites found to be significantly different between the two groups by analysis are highlighted in bold. While SIEVE analysis fails to
attribute significance (p < 0.05) to PCP-induced alterations in the overt concentration of many metabolites for many metabolites in this cluster, the PCP/Control
ratio suggests that the levels of many of these metabolites are markedly altered by PCP-treatment. GSVD analysis reveals that the relationship between the levels
of these metabolites in this cluster are significantly altered by PCP-treatment (p < 0.001) highlighting specific metabolic pathways that may be disrupted in the
PFC of PCP-treated animals. There appears to be an overabundance of Purine (4 metabolites [ko00230]) and Glycerophospholipid (2 metabolites [ko00564]) in the
bottom cluster.
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Altered glycine, serine and threonine metabolism in the
PFC of PCP-treated animals is also consistent with the
hypothesis that glycine and serine represent potential
therapeutic targets for the treatment of schizophrenia
[58]. In addition, we found evidence to suggest that
GABA neurotransmission was also significantly
decreased in the PFC of PCP-treated rats, which may
relate to the compromised integrity of GABAergic inter-
neurones in these animals [3,6], which closely resemble
the GABAergic interneuron alterations seen in schizo-
phrenia. The imbalance in glutamate, glutamine and
GABA levels identified in the PFC of PCP-treated rats
may directly contribute to the hypofrontality (glucose
hypometabolism) seen in these animals, as detected
using the 14C-2-deoxyglucose imaging technique [4], as
all of these metabolites are intimately linked through
metabolic pathways and have a central role in regulating
the coupling of neuronal activity to cerebral glucose
metabolism [59,60].
Our results also suggest that glutamatergic dysfunction
in the PFC of PCP-treated rats is not limited to the disrup-
tion of glutamatergic neurotransmission but also involves
the disruption of the metabolic pathways in which glutat-
mate is involved. For example, altered glutamate metabo-
lism may directly contribute to the disruption of the
Arginine-Proline metabolic pathway in the PFC of PCP-
treated animals. The significant disruption of the Arginine
pathway in PCP-treated animals suggests that prolonged
Table 4 Hypergeometric probability of KEGG defined metabolic pathways in the top cluster in Figure 11
KEGG Path-way
Identity
KEGG Pathway Number of metabolites
in cluster(A)
Total number of pathway
metabolites detected (B)
Hypergeometric
Probability (P (X) ≥ k)
ko00190 Oxidative phosphorylation 1 1 0.224
ko00230 Purine metabolism 3 13 0.598
ko00240 Pyrimidine metabolism 2 6 0.406
ko00250 Alanine, Aspartate and
Glutamate metabolism
4 7 0.043
ko00260 Glycine, Serine and
Threonine metabolism
4 7 0.043
ko00270 Cysteine and Methionine
metabolism
3 7 0.186
map00300 Lysine biosynthesis 1 3 0.538
ko00330 Arginine and Proline
metabolism
7 10 0.001
ko00340 Histidine metabolism 2 5 0.312
ko00410 beta-Alanine metabolism 2 5 0.312
ko00430 Taurine and Hypotaurine
metabolism
1 3 0.538
ko00471 D-glutamine and D-glutamate
metabolism
1 1 0.224
ko00480 Glutathione metabolism 1 5 0.728
ko00564 Glycerophospholipid metabolism 1 11 0.949
ko00600 Sphingolipid metabolism 2 3 0.126
ko00640 Propanoate metabolism 1 2 0.400
map00650 Butanoate metabolism 3 4 0.034
ko00680 Methane metabolism 1 1 0.224
ko00760 Nicotinate and Nicotinamide
metabolism
3 4 0.034
ko00770 Pantothenate and CoA
biosynthesis
2 5 0.312
ko00920 Sulphur metabolism 1 3 0.538
ko04080 Neuroactive ligand-receptor
interaction
4 7 0.043
Table 4 shows the hypergeometric probability of at least the observed number of metabolites arising by chance for a given KEGG defined metabolic pathway in
the top cluster of Figure 11, identified through the GSVD algorithm as being present in control but not PCP-treated animals. Further computational details are
given in the Methods section. The cluster size was 22 metabolites from a total population of 98. There was a significant over representation of metabolites of (i)
Alanine, Aspartate and Glutamate metabolism [ko00250], (ii) Arginine and Proline metabolism [ko00330], (iii) Butanoate metabolism [ko00650], (iv) Nicotinate and
Nicotinamide metabolism [ko00760], (v) Glycine, Serine and Threonine metabolism and (vi) those metabolites active as neurotransmitter ligands [ko04080] (all
highlighted in bold) suggesting that these pathways are disrupted in the PFC of PCP-treated animals.
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NMDA receptor hypofunction may result in disrupted
nitric oxide (NO) signalling in the PFC. There is increasing
evidence that NO signalling is directly linked to NMDA
receptor activity through regulation of the enzyme nitric
oxide synthase (NOS) [61] and that NO signaling contri-
butes to the deficits in cognition that arise from acute
NMDA receptor blockade [62,63]. The finding that Citrul-
line levels, a metabolite in the Arginine-Proline pathway,
are significantly decreased in the PFC of the PCP-treated
rats in this study further supports the suggestion that
NOS activity is altered in the PFC of these animals, as this
metabolite is formed by NOS when it releases NO from L-
arginine. This suggests that NMDA receptor hypofunction
may underlie the decreased NOS activity and protein
expression levels reported in the PFC of schizophrenia
patients [64] and may contribute to the cognitive deficits
seen in this disorder.
In addition to quantitatively defining the specific meta-
bolic pathways altered by experimental manipulation, our
results suggest that the GSVD algorithm can identify dis-
crete series of metabolic reactions altered by experimen-
tal manipulation. In this way, while we found no
significant evidence to support the widespread disruption
of purine metabolism, or the significant disruption of any
other KEGG defined metabolic pathway in the bottom
cluster as detected using the GSVD, we did find evidence
in this cluster to suggest that a specific series of purine
reactions were significantly disrupted in the PFC of PCP-
treated animals. These disrupted purinergic reactions in
the PFC of PCP-treated animals were:
Xanthine∗ ← Hypoxyanthine∗ ↔ Inosine∗ ← IMP∗ → adenylosuccinate∗
∗denotes significantly increased levels in the PFC of PCP - treated rats (SIEVE analysis)
∗denotes series of reactions disturbed in the PFC of PCP - treated rats(GSVD analysis)
This result suggests that the activity of adenylosucci-
nate synthase (ADSS), the enzyme responsible for the
conversion of IMP to adenylosuccinate, may be signifi-
cantly increased in the PFC of PCP-treated animals. An
increase in the functional activity of this enzyme could
Table 5 Hypergeometric probability of KEGG defined metabolic pathways in bottom cluster in Figure 11
KEGG Path-way
Identity
KEGG Pathway Number of metabolites
in cluster(A)
Total number of pathway
metabolites detected (B)
Hypergeometric
Probability (P (X) ≥ k)
ko00010 Glycolysis/Gluconeogenesis 1 1 0.184
ko00051 Fructose and Mannose
metabolism
1 1 0.184
ko00052 Galactose metabolism 1 1 0.184
ko00071 Fatty acid metabolism 1 1 0.184
ko00230 Purine metabolism 4 13 0.191
ko00260 Glycine, Serine and Threonine
metabolism
1 7 0.770
ko00270 Cysteine and Methionine
metabolism
1 7 0.770
ko00340 Histidine metabolism 1 5 0.646
ko00410 beta-Alanine metabolism 1 5 0.646
ko00430 Taurine and Hypotaurine
metabolism
1 3 0.460
ko00440 Phosphonate and
Phosphinate metabolism
1 2 0.335
ko00480 Glutathione metabolism 1 5 0.646
ko00561 Glycerolipid metabolism 1 2 0.335
ko00562 Inositol Phosphate
metabolism
1 2 0.335
ko00564 Glycerphopholipid
metabolism
2 11 0.642
ko00620 Pyruvate metabolism 1 2 0.335
map00650 Butanoate metabolism 1 4 0.562
ko00730 Thiamine metabolism 1 1 0.184
ko00770 Pantothenate and CoA
biosynthesis
1 5 0.646
map00920 Sulphur metabolism 1 3 0.460
Table 5 shows the hypergeometric probability of randomly seeing at least the observed number of metabolites of a given KEGG pathway in the bottom cluster
of Figure 11, identified though the GSVD algorithm as being present in control animals but not in PCP-treated animals. There was no evidence for a particular
over-abundance of metabolites from any given KEGG pathway in this cluster. Cluster size is 18 metabolites from a total population of 98.
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result in both the increased level of adenylosuccinate
and the altered balance in the enzyme’s downstream
metabolites (IMP, Inosine, Hypoxanthine, Xanthine)
seen in the PFC of PCP-treated animals. While the
influence of prolonged NMDA receptor hypofunction
on the functional activity of this specific enzyme
remains to be confirmed, and clearly warrants further
systematic investigation, the recent finding of altered
ADSS gene expression in schizophrenia [65] and the
association of ADSS gene polymorphisms with schizo-
phrenia [66] further highlights a potential role for this
metabolic pathway in this disorder. In addition, a role
for this metabolic pathway in cognition and schizophre-
nia is supported by the observation that inherited defi-
ciency in the enzyme responsible for the breakdown of
adenylosuccinate (ASL) results in mental retardation
and autistic features [67,68]. Furthermore, the ASL gene
maps to chromosome 22q13.1-q13.2 in humans [69] and
these chromosomal loci have been repeatedly linked to
schizophrenia [70-72]. The disruption of this metabolic
pathway may also contribute to the reduced rate of cer-
ebral glucose metabolism in the PFC of PCP-treated ani-
mals [3,4] as ASL deficiency results in hypometabolism
in frontal cortical structures [73]. Overall, these results
suggest that the potential role of this specific series of
metabolic reactions and its enzymes in cognition and
schizophrenia warrants further investigation.
Conclusions
This work addresses the scenario where a pair of net-
works describes two different patterns of connection
between a common set of nodes. We argued from first
principles that the Generalized Singular Value Decom-
position (equation (4)) can form the basis of a very
useful computational tool. In practice, we have shown
that this new computational network reordering tech-
nique was able to identify alterations in metabolic
pathways in the PFC of rats treated subchronically
with PCP that may contribute to the PFC dysfunction
and cognitive deficits seen in these animals. Further-
more, the metabolic pathways identified as being dis-
rupted in the PFC of PCP-treated rats trough the
application of this new computation technique clearly
overlap with those metabolic species known to be dis-
rupted in schizophrenia. Applying this new algorithm
in this way also identified novel pathways that may
also be relevant to schizophrenia. In this way we iden-
tified alterations in glutamate metabolism and meta-
bolic pathways central to glutamatergic
neurotransmission, alterations in arginine and proline
metabolism and the disruption of a novel series of pur-
ine reactions that may contribute to the PFC dysfunc-
tion and cognitive deficits seen in schizophrenia.
Methods
Chemicals
The solvents used for the study were purchased from
the following sources: Acetonitrile, methanol and
chloroform (Fisher Scientific, Leicestershire, UK) and
formic acid (VWR, Poole, UK). All chemicals used were
of analytical reagent grade. A Direct Q-3® water purifi-
cation system (Millipore, Watford, UK) was used to pro-
duce HPLC grade water which was used in all analysis.
Standards for 90 common bio-molecules were also pur-
chased which were used to characterize the ZIC-HILIC
column (Sigma Aldrich, Dorset UK).
Animals
All experiments were completed using male Lister
Hooded rats (Harlan-Olac, UK) housed under standard
conditions (21°C, 45-65% humidity, 12-h dark/light cycle
(lights on 0600h) with food and drinking water available
ad libitum). All manipulations were carried out at least
1 week after entry into the facility and all experiments
were carried out under the Animals (Scientific Proce-
dures) Act 1986. Animals received either sub-chronic
treatment with vehicle (0.9% saline, i.p., n = 5) or
2.58mg.kg-1 PCP.HCl (i.p., Sigma Aldrich, UK) once
daily for five consecutive days (n = 5). At 72 hours after
the final drug treatment dose animals were sacrificed
and the brain rapidly dissected out and frozen in isopen-
tane (-40°C) and stored at -80°C until sectioning. Frozen
brains were sectioned (20 μM) in the coronal plane in a
cryostat (-20°C). Tissue sections from the prefrontal cor-
tex (PFC, Bregma +4.70mm to Bregma +3.20mm) were
collected in 4ml glass vials with reference to a stereotac-
tic rat brain atlas [74] and stored at -80°C until further
preparation for LC-MS analysis.
Extraction of polar metabolites from brain samples for
LC-MS analysis
Extraction of polar metabolites from brain tissue was
carried out using the two-step extraction method
described previously [75], using methanol, water and
chloroform for the optimal extraction of polar metabo-
lites. A hand held homogenizer was used to homogenize
the samples once in solution. For preparation of samples
for LC-MS analysis 200 μl of the collected polar extract
was added to 600 μl of 1 : 1 acetonitrile:water solution
to produce a final solvent:sample ratio of 3 : 1. The
samples were then filtered using Acrodisc 13mm syringe
filters with 0.2 μm nylon membrane (Sigma Aldrich)
before LC-MS analysis.
LC-MS analysis of polar metabolites
Experiments were carried out using a Finnigan LTQ
Orbitrap (Thermo Fisher, Hemel Hempstead, UK) using
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30000 resolution. Analysis was carried out in positive
mode over a mass range of 60-1000 m/z. The capillary
temperature was set at 250°C and in positive ionization
mode the ion spray voltage was 4.5 kV , the capillary
voltage 30 V and the tube lens voltage 105 V . The
sheath and auxiliary gas flow rates were 45 and 15,
respectively (units not specified by manufacturer). A
ZIC-HILIC column (5 μm, 150 × 4.6 mm; HiChrom,
Reading, UK) was used in all analysis and a binary gradi-
ent method was developed which produced good polar
metabolite separation. Solvent A was 0.1% v/v formic
acid in HPLC grade water and solvent B was 0.1% v/v
formic acid in acetonitrile. A flow rate of 0.3 ml/min.
was used and the injection volume was 10 μl. The gradi-
ent programme used was 80% B at 0 min. to 50% B at
12 min. to 20% B at 28 min. to 80% B at 37 min., with
total run time of 45 minutes. The instrument was exter-
nally calibrated before analysis and internally calibrated
using lock masses at m/z 83.06037 and m/z 195.08625.
Samples were analysed sequentially and the vial tray
temperature was set at a constant temperature of 4°C.
Data preparation and analysis
Determination of overt alterations in metabolite levels
between experimental groups
The software program Xcalibur (version 2.0) was used
to acquire the LC-MS data. The raw Xcalibur data files
from version 1.2 (Thermo Fisher, Hemel Hempstead,
UK). SIEVE software (Thermo-Fisher Scientific) was
used to identify all metabolites affected by drug treat-
ment by calculating a p-value and ratio based on the dif-
ference in average intensities of individual peaks, which
correspond to different metabolites, between PCP-trea-
ted and control animals. A significant difference in the
level of each metabolite between groups was set at p
-value < 0.05 and/or ratio less than 0.5 for downregu-
lated metabolites and greater than 2 for upregulated
metabolites. The ratio is the fold change in average peak
intensities from control and treatment groups. For
metabolite identification the masses of the polar meta-
bolites were compared to the exact masses of 6000 bio-
molecules using an in-house developed macro (Excel,
Microsoft 2007).
Hypergeometric probability testing
The hypergeometric probability test was used to calcu-
late the probability of finding at least the observed num-
ber of metabolites of a given pre-defined metabolic
pathway (as defined on the KEGG pathway database) in
the clusters identified through the GSVD algorithm,
with knowledge of the total number of metabolites pre-
sent in that pathway detected by LC-MS in these sam-
ples. The hypergeometric probability test was used to
identify whether any of the KEGG defined metabolic
pathways were significantly over-represented in any of
the GSVD identified clusters. In its general form hyper-
geometric probability allows the calculation of the prob-
ability of observing at least (k) metabolites from a given
defined KEGG pathway in a defined cluster of metabo-
lites (n) given the total number of metabolites (N) and
the total number of metabolites from the pathway in
question (m). The probability mass function of hyper-
geometric distribution is:
f (k; N, m, n) = P(X = k) =
(
m
k
) (
N−m
n−k
)
(
N
n
) . (9)
So here the probability is calculated using the formula
P(X ≥ k) =
m∑
i=k
(
m
i
) (
N−m
n−i
)
(
N
n
) . (10)
Significant over-representation of a given functional
group in any GSVD defined significant cluster was set
by a hypergeometric probability threshold of 0.05.
Additional material
Additional file 1: Table S1 - List of all metabolites detected by LC-
MS in the PFC of Control and PCP-treated animals. Table S1 Legend:
The molecular formula and tentative molecular identity for each
metabolite detected in the PFC of control and PCP-treated animals is
shown. In addition, the KEGG molecular identity and the KEGG metabolic
pathways in which a metabolite is involved are also shown. The ratio
difference in metabolite concentration and the significance of this
change (p-value), as determined by SIEVE analysis (see Methods section),
are also shown. Those metabolites found to be significantly different
between the two groups are highlighted in bold. The most prominent
alterations in KEGG defined metabolic pathways appeared to be in (i)
alanine, aspartate and glutamate metabolism (3 metabolites [ko00250]),
(ii) phenylalanine, tyrosine and tryptophan metabolism (3 metabolites
[ko00360]), (iii) purine metabolism (2 metabolites [ko00230]) and (iv)
butanoate metabolism (2 metabolites [ko00650]). KEGG defined
metabolic pathways; ko00250: Alanine, Aspartate and Glutamate
metabolism; ko00627: Aminobenzoate degradation; ko00330: Arginine
and Proline metabolism; ko00410: beta-Alanine metabolism; ko00780:
Biotin metabolism; map00650: Butanoate metabolism; ko04973:
Carbohydrate metabolism; ko00270: Cysteine and Methionine
metabolism; ko00071: Fatty acid metabolism; ko00051: Fructose and
Manose metabolism; ko00052: Galactose metabolism; ko00471:
Glutamine and Glutamate metabolism; k00480: Glutathione metabolism;
ko00561: Glycerolipid metabolism; ko00564: Glycerophospholipid
metabolism; ko00260: Glycine, Serine and Threonine metabolism;
ko00010: Glycolysis/Gluconeogenesis; ko00340: Histidine metabolism;
ko00562: Inositol Phosphate metabolism; map00300: Lysine
biosynthesis; ko00310: Lysine degradation; ko00430: Methionine
metabolism; ko04080; Neuroactive ligand-receptor interaction; ko00760:
Nicotinate and Nicotinamide metabolism; ko00190: Oxidative
phosphorylation; ko00770: Pantoate and CoA biosynthesis; ko00550:
Peptidoglycan biosynthesis; ko00360: Phenylalanine metabolism;
ko00400: Phenylalanine, Tyrosine and Tryptophan biosynthesis;
ko00440: Phosphonate and Phosphinate metabolism; ko00640:
Propanoate metabolism; ko00230: Purine metabolism; ko00240:
Pyrimidine metabolism; ko00620: Pyruvate metabolism; ko00500: Starch
and Sucrose metabolism; ko00600: Sphingolipid metabolism; ko00920:
Sulphur metabolism; ko00430: Taurine and Hypotaurine metabolism;
ko00730: Thiamine metabolism; ko00380: Tryptophan metabolism;
ko00350: Tyrosine metabolism; ko00400: Tyrosine and Tryptophan
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biosynthesis; ko00290; Valine, Leucine and Isoleucine biosynthesis;
ko00280: Valine, Leucine and Isoleucine degradation. NA denotes a
metabolite not associated with a KEGG compound ID or KEGG pathway.
Additional file 2: 98 × 98 matrix of between metabolite correlations
in the PFC of control animals. The 98 × 98 matrix of the Pearson’s
correlation coefficients (Fisher z-transformed) between all metabolites
detected in the prefrontal cortex of control (saline-treated) animals by
LC-MS analysis is shown.
Additional file 3: 98 × 98 matrix of between metabolite correlations
in the PFC of PCP-treated animals. The 98 × 98 matrix of the Pearson’s
correlation coefficient (Fisher z-transformed) between all metabolites
detected in the prefrontal cortex of PCP-treated animals by LC-MS
analysis is shown.
Additional file 4: Table S2 - Table showing the axes labels in
Figures 9, 10and 11. In Table S2 the position of each metabolite in the
original ordering (Figure 4) is shown. In the columns for Figures 5 and 6,
the corresponding numbers indicating the new position of each
metabolite (node) in the matrix when reordered by the first column of X
-T and the final column of X -T, respectively, is shown.
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